文献速递基础与转化研究临床试验与 GCP

嵌合抗原受体T细胞治疗后胶质母细胞瘤消退

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
PubMed 文献 · N Engl J Med · 2016-01-01

一例复发性多灶性胶质母细胞瘤患者接受靶向白细胞介素-13受体α2(IL13Rα2)的嵌合抗原受体(CAR)T细胞治疗,220天内经两种颅内途径多次输注,未出现3级或以上毒性,全部颅内及脊髓肿瘤消退,细胞因子和免疫细胞水平相应升高,缓解持续7.5个月。

要点

  • 靶向IL13Rα2的CAR T细胞经颅内途径多次输注,未出现3级或以上毒性。
  • 治疗后全部颅内及脊髓肿瘤消退,脑脊液中细胞因子和免疫细胞水平相应升高。
  • 临床缓解在CAR T细胞治疗开始后持续7.5个月。

核心结论

  • 靶向IL13Rα2的CAR T细胞颅内输注后,复发性多灶性胶质母细胞瘤患者全部颅内及脊髓肿瘤消退,缓解持续7.5个月。

研究设计与样本

  • 一例复发性多灶性胶质母细胞瘤患者接受靶向IL13Rα2的CAR T细胞治疗。
  • 220天内经两种颅内途径多次输注:先输注入切除肿瘤腔,后输注入脑室系统。

主要发现

  • 颅内输注IL13Rα2靶向CAR T细胞未伴随3级或以上毒性效应。
  • CAR T细胞治疗后观察到全部颅内和脊髓肿瘤消退,脑脊液中细胞因子和免疫细胞水平相应升高。
  • 临床缓解在CAR T细胞治疗开始后持续7.5个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016. PMID: 28029927. doi:10.1056/NEJMoa1610497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。